Autophagy is a cellular catabolic pathway by which long-lived proteins and damaged organelles are targeted for degradation. Activation of autophagy enhances cellular tolerance to various stresses. Recent studies indicate that a class of anticancer agents, histone deacetylase (HDAC) inhibitors, can induce autophagy. One of the HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA), is currently being used for treating cutaneous T-cell lymphoma and under clinical trials for multiple other cancer types, including glioblastoma. Here, we show that SAHA increases the expression of the autophagic factor LC3, and inhibits the nutrient-sensing kinase mammalian target of rapamycin (mTOR). The inactivation of mTOR results in the dephosphorylation, and thus activation, of the autophagic protein kinase ULK1, which is essential for autophagy activation during SAHA treatment. Furthermore, we show that the inhibition of autophagy by RNAi in glioblastoma cells results in an increase in SAHA-induced apoptosis. Importantly, when apoptosis is pharmacologically blocked, SAHA-induced nonapoptotic cell death can also be potentiated by autophagy inhibition. Overall, our findings indicate that SAHA activates autophagy via inhibiting mTOR and up-regulating LC3 expression; autophagy functions as a prosurvival mechanism to mitigate SAHA-induced apoptotic and nonapoptotic cell death, suggesting that targeting autophagy might improve the therapeutic effects of SAHA. transcription | ATG7 | necrosis H istone deacetylase (HDAC) inhibitors emerge as a new class of therapeutic agents with promising outcomes during the treatment of a wide range of cancer types (1). Hematological malignancies appear to be particularly sensitive to HDAC inhibitors; however, a number of additional cancer types are currently being tested for their response to HDAC inhibition therapy. For an example, suberoylanilide hydroxamic acid (SAHA, vorinostat), which inhibits HDACs 1, 2, 3, and 6, has been approved for treatment against cutaneous T-cell lymphoma and also has modest effects as a single agent on cancers of the prostate, ovaries, breast, colorectal, and glioblastoma (2, 3). Although their precise mode of action remains uncertain, a number of recent data suggest that HDAC inhibitors may induce apoptotic cell death through both chromatin-dependent and -independent mechanisms.
Autophagy is a cellular catabolic pathway by which long-lived proteins and damaged organelles are targeted for degradation. Activation of autophagy enhances cellular tolerance to various stresses. Recent studies indicate that a class of anticancer agents, histone deacetylase (HDAC) inhibitors, can induce autophagy. One of the HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA), is currently being used for treating cutaneous T-cell lymphoma and under clinical trials for multiple other cancer types, including glioblastoma. Here, we show that SAHA increases the expression of the autophagic factor LC3, and inhibits the nutrient-sensing kinase mammalian target of rapamycin (mTOR). The inactivation of mTOR results in the dephosphorylation, and thus activation, of the autophagic protein kinase ULK1, which is essential for autophagy activation during SAHA treatment. Furthermore, we show that the inhibition of autophagy by RNAi in glioblastoma cells results in an increase in SAHA-induced apoptosis. Importantly, when apoptosis is pharmacologically blocked, SAHA-induced nonapoptotic cell death can also be potentiated by autophagy inhibition. Overall, our findings indicate that SAHA activates autophagy via inhibiting mTOR and up-regulating LC3 expression; autophagy functions as a prosurvival mechanism to mitigate SAHA-induced apoptotic and nonapoptotic cell death, suggesting that targeting autophagy might improve the therapeutic effects of SAHA. transcription | ATG7 | necrosis H istone deacetylase (HDAC) inhibitors emerge as a new class of therapeutic agents with promising outcomes during the treatment of a wide range of cancer types (1) . Hematological malignancies appear to be particularly sensitive to HDAC inhibitors; however, a number of additional cancer types are currently being tested for their response to HDAC inhibition therapy. For an example, suberoylanilide hydroxamic acid (SAHA, vorinostat), which inhibits HDACs 1, 2, 3, and 6, has been approved for treatment against cutaneous T-cell lymphoma and also has modest effects as a single agent on cancers of the prostate, ovaries, breast, colorectal, and glioblastoma (2, 3) . Although their precise mode of action remains uncertain, a number of recent data suggest that HDAC inhibitors may induce apoptotic cell death through both chromatin-dependent and -independent mechanisms.
Treatment with HDAC inhibitors most frequently induces apoptosis via the programmed activation of a series of proteases, called caspases (4) (5) (6) . More recently, HDAC inhibition has been also shown to induce autophagy (7, 8) . Unlike apoptosis, the contribution of autophagy to cell death remains controversial and, most likely, context-dependent. Autophagy is a catabolic process by which cytosolic material is targeted for lysosomal degradation by means of double-membrane cytosolic vesicles, termed autophagosomes (9) . The formation of autophagosomes is orchestrated by upstream signaling molecules, including the ULK1 and PI3K complexes, which signal to downstream complexes involved in the nucleation and maturation of the doublemembrane vesicle. Nutrient and energy sensing can directly regulate autophagy by affecting the ULK1 complex, which is comprised of the protein kinase ULK1 and its regulators, ATG13 and FIP200 (10) (11) (12) . Under nutrient-rich conditions, mammalian target of rapamycin (mTOR) directly phosphorylates ULK1 and ATG13 to inhibit the autophagy function of the ULK1 complex. However, amino acid deprivation inactivates mTOR and therefore releases ULK1 from its inhibition. Downstream of the ULK1 complex, in the heart of the autophagosome nucleation and elongation, lie two ubiquitin-like conjugation systems: the ATG12-ATG5 and the LC3-phosphatidylethanolamide (PE) conjugates (13) . During autophagy, free cytosolic LC3 (termed LC3-I) becomes conjugated to PE (termed LC3-II). LC3-II is then incorporated to the growing autophagosome structure that, upon maturation, fuses with the lysosome compartment, leading to the degradation of the autophagosome content.
The encapsulation and degradation of cytosolic materials by autophagy aids in the clearance of damaged organelles and misfolded proteins, and thereby plays an important role in the recycling of macromolecules and energy within the cells. In this context, autophagy may be regarded as a prosurvival mechanism (14) . Hence, autophagy is frequently activated during nutrient deprivation, hypoxia, and a wide range of anticancer therapy. The activation of autophagy has been frequently shown to inhibit the onset of apoptotic and necrotic cell death (15) . However, in cases where autophagy may have an additive role in the death process, autophagy may be regarded as a cell-death mechanism (16). Here, excessive "self-eating" through autophagy may contribute to cell death by a yet unknown mechanism. Therefore, assessing the role of autophagy in a context-dependent manner is crucial, especially when considering whether autophagy-targeting can be used during anticancer therapy.
We have previously shown that SAHA treatment induces potent autophagy (8) . In this study, we provide insights into the mechanism by which SAHA induces autophagy. We also show that autophagy-targeting can enhance SAHA-induced apoptotic and nonapoptotic cell death in glioblastoma cells.
Results
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The authors declare no conflict of interest. (Fig. 1B) . In untreated cells, which mostly express LC3-I, GFP-LC3 showed a cytosolic, diffused localization (Fig. 1B , Left). However, SAHA treatment resulted in the relocalization of GFP-LC3 into punctate structures corresponding to autophagosomes (Fig. 1B, Right) . Furthermore, to test whether SAHA treatment results in the induction of a functional autophagic flux whereby the autophagosome content is targeted for lysosomal degradation, we monitored the degradation of a known autophagy substrate, p62 (17) . As can be seen from Fig.  1C , p62 was dramatically destabilized in the presence of SAHA. This decrease in p62 levels was reverted by Baf A1, suggesting that SAHA can induce lysosome-mediated degradation of autophagy substrates, and thus a functional autophagic flux. Overall, this molecular analysis confirms that SAHA can trigger robust autophagy in MEF cells.
Upon treatment of MEF cells with SAHA for 24 h, we noticed a dramatic increase in the unconjugated form of LC3, LC3-I (Fig. 1D ). This increase is the case even in autophagy-defective ATG3 −/− MEFs. Because HDAC inhibitors were previously shown to impact gene expression, we tested whether the effect of SAHA treatment on LC3 levels was transcriptional. We performed a semiquantitative RT-PCR analysis on RNA extracted from wild-type MEFs that were left untreated or treated with 10 μM of SAHA for 18 h. As shown in Fig. 1E , SAHA treatment indeed increased LC3 transcript levels.
SAHA Induces Autophagy by Suppressing mTOR and Activating the ULK1 Complex. Although transcriptional up-regulation of LC3 can contribute to SAHA-induced autophagy, it is nevertheless insufficient for autophagy initiation, which requires activation of upstream signaling to induce the conversion of LC3-I to LC3-II. The ULK1 complex has been shown to be the most upstream component in the core autophagy pathway and is essential for autophagy induced by various conditions (18, 19) . Therefore, we first tested whether ULK1 activity is essential for SAHA-mediated autophagy. For this purpose, we used MEF cells with genetic deletions of both ULK1 and its functional homolog ULK2 (ULK1/2 double knockout, DKO) (20) . We treated both ULK1/ 2 DKO MEFs and wild-type MEFs with SAHA and assessed the induction of autophagy by monitoring LC3 conversion. As shown in Fig. 2A , unlike wild-type MEFs that contained an intact autophagy response ( Fig. 2A, Upper) , LC3 conversion was defective in ULK1/2 DKO MEFs ( Fig. 2A, Lower) , indicating that SAHA induces autophagy in a ULK1-dependent mechanism. Previous reports suggest that the autophagy function of the ULK1 complex is suppressed by the nutrient-sensing kinase mTOR (10, 12) and mTOR does so by directly phosphorylating ULK1 and its regulator ATG13. This finding prompted us to examine whether SAHA treatment can cause the inactivation of mTOR and thereby activation of the ULK1 complex. Indeed, as shown in Fig. 2B , two well-known mTOR substrates, p70S6K and 4EBP, are dephosphorylated upon SAHA treatment in a similar manner to that upon amino acid starvation. Importantly, in cells treated with SAHA, ULK1 was dephosphorylated and thus activated, as monitored by its faster mobility in SDS/PAGE. These results indicate that SAHA treatment can induce autophagy via relieving the ULK1 complex from inhibition by mTORmediated phosphorylation.
Autophagy Inhibition Accelerates Apoptotic Cell Death in T98G Cells.
To study the role of autophagy in SAHA-induced cancer cell death, we used the glioblastoma cell line, T98G, as a model. First, we show that SAHA can induce autophagy, measured by LC3-I to LC3-II conversion, in these cells (Fig. 3A) . This conversion is dependent upon intact autophagy machinery and is impeded upon shRNA-mediated knockdown of ATG7. Furthermore, we show that GFP-LC3 localizes to punctate structures, autophagosomes, in the presence of SAHA (Fig. 3B) , thus further supporting that SAHA treatment induces autophagy in T98G cells. Subsequently, to investigate the role of autophagy during apoptotic cell death induced by SAHA, we used an in vitro assay to measure caspase-3 activity, and compared the induced apoptosis in T98G cells harboring control shRNA or shRNA against ATG7. Caspase-3 activity was greatly enhanced at various concentrations of SAHA in ATG7 knockdown cells compared with control knockdown (Fig.  4A ). This increase in caspase-3 activity is specific to caspase activation and can be suppressed by cotreating cells with the pancaspase inhibitor, zVAD. We also confirmed that ATG7 knockdown increases caspase-3 activation in the presence of SAHA by Western blot as indicated by the accumulation of the active, cleaved form of caspase-3 in these cells (Fig. 4B) . Furthermore, we measured cell viability during SAHA treatment, and compared control and ATG7 knockdown cells. Consistently, ATG7 knockdown resulted in a decrease in cell survival during SAHA treatment compared with control knockdown cells (Fig. 4C ), which correlates with an increase in cell detachment (Fig. 4D) . Overall, these results indicate that autophagy protects T98G cells from apoptotic cell death and enhances cell survival in the presence of SAHA.
Autophagy Suppression Decreases Cell Survival in the Absence of Apoptosis. We have previously shown that SAHA can also induce nonapoptotic cell death when apoptosis is blocked (8) . In our assays, cells treated with zVAD, which completely abolished caspase activation (Fig. 4A) , still underwent autophagy induced by SAHA (Fig. 5A) . To test whether autophagy may cause an increased cell survival in the absence of apoptotic cell death, we measured cell survival in cells cotreated with SAHA and zVAD. As shown in Fig. 5B , ATG7 knockdown, which blocks autophagy at least in part (Fig. 5A ), results in a decreased cell survival during SAHA and zVAD cotreatment. This effect correlates with an increase in cell detachment of ATG7 knockdown cells compared with control knockdown (Fig. 5C ). In addition, the clonogenic survival of cells treated with SAHA and zVAD was reduced in ATG7 knockdown cells compared with control knockdown cells (Fig. 5D ), further suggesting that ATG7 knockdown reduces cell survival during SAHA and zVAD treatment. These results demonstrate that autophagy acts as a protective mechanism to reduce SAHA-induced nonapoptotic cell death.
Discussion
In this study, we investigate the mechanisms by which the HDAC inhibitor SAHA induces autophagy and the role of autophagy in cancer cell survival during SAHA treatment. We found that SAHA can enhance autophagy by influencing the autophagy pathway at various points. Furthermore, we provide evidence that autophagy inhibition results in a higher level of apoptotic and nonapoptotic cell death in response to SAHA treatment. Overall, our study suggests that targeting autophagy during cancer treatment with SAHA may augment therapeutic effects. Mechanistically, SAHA regulates autophagy by both inducing LC3 expression transcriptionally and inactivating mTOR, which might be indirect or not at all related to transcription. Previously, HDAC inhibitors were shown to both increase and decrease the transcriptional expression of certain genes. HDAC inhibitors can induce cell-cycle arrest by increasing the expression of the cellcycle inhibitor p21, and decreasing the expression of cyclindependent kinases required for cell cycle progression (21) . In addition, HDAC inhibition resulted in impaired DNA repair during cytotoxic damage at least in part by downregulating the expression of double-stranded break repair machinery including Ku70, RAD51, and BRCA1/2 (22, 23) . In the case of LC3, we observed a transcription-dependent increase in LC3 levels induced by SAHA. During persistent autophagy, LC3 protein levels may drop as LC3 is conjugated to autophagosome membrane, which in turn is targeted for degradation upon fusion with the lysosome compartment. Therefore, up-regulating LC3 transcription during autophagy becomes an important mechanism to avoid the exhaustion of the pathway during prolonged treatment. On the other hand, although transcriptional up-regulation of LC3 may be important to ensure persisting autophagy, it is not sufficient to induce autophagy. Indeed, our results indicate that SAHA can cause the inactivation of mTOR, thus inducing autophagy through a ULK1 complex-dependent mechanism (Fig. 2) . The exact mechanism by which mTOR is inactivated by HDAC inhibition remain to be unraveled. SAHA does not have an effect on mTOR levels or acetylation, using the conditions empolyed in this study (Fig. S1) . Therefore, it is not clear whether SAHA inactivates mTOR via inhibition of histone deacetylation and thus transcription of certain genes or via inhibition of deacetylation of a nonhistone protein that is involved in mTOR regulation.
As with many other anticancer therapies, SAHA-induced autophagy appears to act as a prosurvival mechanism to counteract the cytotoxic activity of SAHA. Autophagy may delay the onset of apoptosis during SAHA treatment through various mechanisms including clearance of reactive oxygen species that are generated during SAHA treatment (24) , clearance of p62-containing protein aggregates, which may accumulate during HDAC inhibition, and clearance of damaged mitochondria (25) .
Abrogated apoptosis frequently contributes to chemotherapy resistance. SAHA was previously shown to induce nonapoptotic cell death in cells deficient in apoptotic machinery or cotreated with zVAD (8, 26) . The nature of this type of nonapoptotic cell death triggered by SAHA remains unresolved. Our preliminary studies suggest that inhibiting RIP1 kinase, a key player in death receptor-mediated necrosis by necrostatin A (27), does not inhibit cell death triggered by SAHA and zVAD cotreatment (Fig.  S2) . However, this result does not rule out necrosis, as RIP1-independent necrosis has been previously reported (28) .
A wide range of targeted cancer therapeutic agents, such as mTOR inhibitors, AKT inhibitors, and proteasome inhibitors were shown to induce autophagy in cancer cells as conventional Fig. 3 . SAHA induces autophagy in T98G glioblastoma cells. (A) T98G glioblastoma cell lines expressing either control shRNA or shRNA targeting ATG7 sequences were treated with SAHA using the indicated concentrations and times. Cell lysates were then subjected to Western blot analysis using the following antibodies: anti-ATG7 to confirm knockdown efficiency, anti-LC3 to analyze autophagy induction and anti-actin as a loading control. (B) T98G stably expressing GFP-LC3 were grown on glass cover-slips and treated with 10 μM SAHA for the indicated times. Slides were then fixed with PFA and analyzed by confocal microscopy using a 20× magnification objective.
chemotherapies (29) . The exact role of autophagy in these treatments may vary, depending on the contexts of individual tumors and treatments. As suggested by this study, when treating resistant tumors, such as recurrent glioblastoma (30-32), autophagytargeting might prove to be a unique combinational therapy that can potentiate the anticancer effect of SAHA treatment.
Materials and Methods
Cell Culture. Wild-type MEF cells, ULK1/2 DKO MEFs, ATG3 knockout (ATG3 −/− ) MEFs, and T98G glioblastoma cell line were cultured in DMEM supplemented with 10% (vol/vol) FBS, L-Glutamine (2 mM), pencillin (10 Units/mL), and streptomycin (0.1 mg/mL). Cells stably expressing GFP-LC3 were generated by retroviral infection using pBabe-GFP-LC3 followed by blasticidin selection. For amino acid starvation experiments, cells were grown in DMEM lacking amino acids and serum for 2 h before harvest, as described previously (33) .
Reagents and Antibodies. The following drugs were dissolved in DMSO: SAHA (Chemietek), zVAD-FMK (Enzo Life Sciences), Baf A1 (Sigma).
For Western blot analysis, the following antibodies were used: anti-LC3 (Sigma; #L7543); anti-Actin (Sigma; #A5316); anti-ULK1 (Sigma; #A7481); anti-caspase-3 (Cell Signaling; clone 8G10); anti-S6K (Cell Signaling; total #2708, phospho #9205); anti-4-EBP (Cell Signaling; #9452); anti-ATG7 (Santa Cruz; clone H300); anti-p62/SQSTM1 (MBL, #PM045B).
SAHA Treatment. MEF and T98G cells were seeded at 3 × 10⁵ per well in a sixwell dish. Twenty-four hours later, fresh medium containing the indicated concentration of SAHA was added on the cells. Treatment with zVAD along with SAHA was included as indicated at a final concentration of 10 μM. The lysosome degradation inhibitor, Baf A1, was added 2 h before harvest at a final concentration of 20 nM.
Microscopy. For microscopy, T98G or MEF cells stably expressing GFP-LC3 were grown on glass cover-slips in a six-well plate. Twenty-four hours later, SAHA treatment was applied as indicated. Cover-slips were then fixed with 3.7% (vol/vol) paraformaldehyde in 20 mM Hepes pH 7.5 for 30 min at room temperature. Cover-slips were then mounted on microscope slides and processed using Nikon Confocal Microscope using the 20× or 60× magnification Resazurin dye was then added to each well and plate and was further incubated for 3 h before measurement of the Resazurin fluorescence. Cell numbers were then deduced from a standard curve and survival was measured relative to untreated samples, which corresponded to 100% survival. Error bars correspond to SEM values of at least three independent assays. (D) T98G cells expressing control or ATG7 shRNA were seeded in a six-well plate, left untreated, or treated with SAHA for 48 h. Phase-contrast images of cells were then captured under Nikon fluorescent scope using a 20× magnification objective. objectives. For cell death imaging, T98G cells were grown in six-well plates for 24 h before treatment with SAHA, as indicated. Cell detachment was then acquired using a Nikon Fluorescent scope (20× magnification objective).
RNAi. RNAi-mediated knockdown was performed using a doxycycline inducible pTRIPz vector (Thermo Scientific) expressing shRNAmir against ATG7 or nontarget control (ATG7 KD or control KD). The sequences targeted by the shRNAmir were as follows, ATG7 KD: 5′ CCAGTTCAGAGCTAAATAATA; control KD: 5′ CAACAAGATGAAGAGCACCAA. Lentiviruses harboring the knockdown sequences were used to infect T98G cells. Cells when then selected with puromycin for at least 3 d, followed by addition of doxycycline to induce shRNA and red fluorescent protein expression. Cell sorting by FACS was performed to select the 20% highest red fluorescent protein-expressing population, which was further propagated and tested for knockdown.
RT-PCR. MEF cells were harvest by directly lysing in RLT lysing reagent followed by RNA extraction using RNeasy (Qiagen) according to the manufacturer's instruction (Qiagen). Reverse transcription using 1 μg of RNA as a template was used to produce cDNA using iScript cDNA synthesis kit (BioRad) according to the manufacturer's instructions. PCR was then performed to amplify LC3 and GAPDH sequences.
Caspase Assay. Floating and attached cells (collected by trypsinization) were lysed. Twenty micrograms of cell lysate was then mixed with caspase-3 (Apopain) substrate Rhodamine 110 (AnaSpec; final concentration, 1.5 μM) on ice in a final volume of 20 μL. Samples were then immediately loaded on 96-well plates and fluorescence was measured at 30°C for 180 min using TECAN at excitation and emission 485 nm and 535 nm, respectively. Average relative fluorescence units (RFU) at 60 min were plotted and SEM of at least three independent assays.
Resazurin Cell Survival Assay. T98G cells were seeded in 96-well plates (500 cells per well). Twenty-four hours later, treatment with SAHA with or without zVAD was initiated as indicated. The Resazurin dye was added to each well according to the manufacturer's instruction (R&D Systems). Three hours later, fluorescence in plate was measured using a TECAN fluorescence plate reader with excitation and emission of 535 nm and 590 nm, respectively. Cell numbers were derived from a standard curve and cell survival calculated as a percentage of mock treatment, which corresponded to 100% survival. Error bars correspond to SEM of at least three independent assays.
Colony Formation Assay. T98G cells were seeded in 6-cm dishes, 24 h later cells were treated with SAHA (20 μM) and zVAD (10 μM) for a further 48 h. Inhibitors were then washed off and cells were grown in fresh growth media for 2 wk before fixation with 10% (vol/vol) formaldehyde and staining with Giemsa stain (Sigma) to visualize cell colonies.
